332 related articles for article (PubMed ID: 25655760)
1. Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.
Quiroga D; Aldhamen YA; Appledorn DM; Godbehere S; Amalfitano A
Cancer Immunol Immunother; 2015 Apr; 64(4):479-91. PubMed ID: 25655760
[TBL] [Abstract][Full Text] [Related]
2. Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2.
Aldhamen YA; Seregin SS; Kousa YA; Rastall DP; Appledorn DM; Godbehere S; Schutte BC; Amalfitano A
Cancer Gene Ther; 2013 Oct; 20(10):564-75. PubMed ID: 23949283
[TBL] [Abstract][Full Text] [Related]
3. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
4. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
5. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
[TBL] [Abstract][Full Text] [Related]
6. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.
Saha A; Baral RN; Chatterjee SK; Mohanty K; Pal S; Foon KA; Primus FJ; Krieg AM; Weiner GJ; Bhattacharya-Chatterjee M
Cancer Immunol Immunother; 2006 May; 55(5):515-27. PubMed ID: 16044253
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
Kantor J; Irvine K; Abrams S; Kaufman H; DiPietro J; Schlom J
J Natl Cancer Inst; 1992 Jul; 84(14):1084-91. PubMed ID: 1619682
[TBL] [Abstract][Full Text] [Related]
8. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
9. A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target.
Appledorn DM; Aldhamen YA; Depas W; Seregin SS; Liu CJ; Schuldt N; Quach D; Quiroga D; Godbehere S; Zlatkin I; Kim S; McCormick JJ; Amalfitano A
PLoS One; 2010 Mar; 5(3):e9579. PubMed ID: 20221448
[TBL] [Abstract][Full Text] [Related]
10. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
[TBL] [Abstract][Full Text] [Related]
11. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
12. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model.
Kim HS; Kim CH; Park MY; Park JS; Park HM; Sohn HJ; Kim HJ; Kim SG; Oh ST; Kim TG
Immunol Lett; 2010 Jun; 131(1):73-80. PubMed ID: 20211203
[TBL] [Abstract][Full Text] [Related]
13. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
[TBL] [Abstract][Full Text] [Related]
14. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
McLaughlin JP; Schlom J; Kantor JA; Greiner JW
Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
[TBL] [Abstract][Full Text] [Related]
15. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
16. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG
Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
[TBL] [Abstract][Full Text] [Related]
19. A carcinoembryonic antigen polynucleotide vaccine for human clinical use.
Conry RM; LoBuglio AF; Loechel F; Moore SE; Sumerel LA; Barlow DL; Pike J; Curiel DT
Cancer Gene Ther; 1995 Mar; 2(1):33-8. PubMed ID: 7621253
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.
Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G
Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
